Epidermal disease

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:79353
Who is this for?
Show terms as
29Specialists8Treatment centers

Where are you in your journey?

ℹ
UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Oct 2026Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

National Cancer Institute (NCI) — PHASE1

TrialRECRUITING
Apr 2026A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens

Shanghai Pulmonary Hospital, Shanghai, China — PHASE4

TrialNOT YET RECRUITING
Apr 2026Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial

Jonsson Comprehensive Cancer Center — PHASE2

TrialNOT YET RECRUITING
Apr 2026A Pilot Study on the Efficacy of 2% Cholesterol Cream in Preventing Transepidermal Water Loss and Clinical Symptoms in Mild to Moderate Atopic Dermatitis

Institute of Dermatology, Thailand — NA

TrialENROLLING BY INVITATION
Apr 2026A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

EpiBiologics — PHASE1

TrialRECRUITING
Mar 2026TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC

Tianjin Medical University General Hospital — EARLY_PHASE1

TrialNOT YET RECRUITING
Mar 2026A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Regeneron Pharmaceuticals — PHASE2

TrialRECRUITING
Mar 2026Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment

TransThera Sciences (Nanjing), Inc. — PHASE2

TrialRECRUITING
Mar 2026The Value of Adding Mini-oral Pulse Steroid Therapy in Preventing Peri-lesional Halo Post Non-cultured Epidermal Cell Suspension (NCES) in Cases With Stable Segmental and Non-acral Vitiligo.

Cairo University — PHASE4

TrialNOT YET RECRUITING
Mar 2026The Value of Methotrexate in NCES for Stable Vitiligo

Cairo University — PHASE4

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Epidermal disease.

View clinical trials →

Clinical Trials

View all trials with filters →

No actively recruiting trials found for Epidermal disease at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Epidermal disease community →

Specialists

Showing 25 of 29View all specialists →
GL
Global Clinical Leader
Specialist
PI on 44 active trials4 Epidermal disease publications
AM
Arun Rajan, M.D.
BETHESDA, MD
Specialist
PI on 11 active trials
PL
Project Leader
Specialist
PI on 11 active trials
BP
BioNTech Responsible Person
Specialist
PI on 18 active trials
SM
Si-Yu Wang, MD
Specialist
PI on 3 active trials
PP
Passeron Thierry, PhD
Specialist
PI on 10 active trials
GL
Global Team Leader
Specialist
PI on 6 active trials
AM
Armando Santoro, MD
Specialist
PI on 19 active trials
EM
Evanthia Galanis, MD
ROCHESTER, MN
Specialist
PI on 9 active trials
YM
Yuankai Shi, MD
Specialist
PI on 13 active trials
MM
Mario Lacouture, MD
NEW YORK, NY
Specialist
PI on 3 active trials
BI
Boehringer Ingelheim
Peoria, Arizona
Specialist

Rare Disease Specialist

PI on 123 active trials
RD
Reshma L Mahtani, D.O.
PLANTATION, FL
Specialist
PI on 1 active trial
DM
David B. Page, MD
Specialist
PI on 1 active trial
DP
Daniel Tan, BSc, MBBS, PhD
Specialist
PI on 1 active trial
JG
Jonathan W Goldman
Specialist
PI on 2 active trials
RM
Rachel Freedman, MD, MPH
Specialist
PI on 2 active trials
BD
Bokemeyer, Prof. Dr.
Specialist
PI on 1 active trial
DM
Deirdre Cohen, MD
TUCSON, AZ
Specialist
PI on 2 active trials
MM
Matthew Gumbleton, MD
SALT LAKE CITY, UT
Specialist
PI on 1 active trial
SM
Sara Hurvitz, MD
SEATTLE, WA
Specialist
PI on 1 active trial
TM
Thomas W Flaig, MD
AURORA, CO
Specialist
PI on 1 active trial
GP
Gregory Springett, M.D., Ph.D.
TAMPA, FL
Specialist
PI on 2 active trials
PM
Philip Leese, MD
OVERLAND PARK, KS
Specialist
PI on 2 active trials
PM
Payal D. Shah, MD
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center ↗

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center ↗

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program ↗

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site ↗

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site ↗

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site ↗

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine ↗

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program ↗

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Epidermal disease.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Epidermal diseaseForum →

No community posts yet. Be the first to share your experience with Epidermal disease.

Start the conversation →

Latest news about Epidermal disease

Disease timeline:

New recruiting trial: PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis

A new clinical trial is recruiting patients for Epidermal disease

New recruiting trial: A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

A new clinical trial is recruiting patients for Epidermal disease

New recruiting trial: A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

A new clinical trial is recruiting patients for Epidermal disease

New recruiting trial: Observational Study of Afatinib 30 mg Daily

A new clinical trial is recruiting patients for Epidermal disease

New recruiting trial: A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy

A new clinical trial is recruiting patients for Epidermal disease

New recruiting trial: Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

A new clinical trial is recruiting patients for Epidermal disease

New recruiting trial: A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer

A new clinical trial is recruiting patients for Epidermal disease

New recruiting trial: Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer

A new clinical trial is recruiting patients for Epidermal disease

New recruiting trial: Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks

A new clinical trial is recruiting patients for Epidermal disease

New recruiting trial: Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

A new clinical trial is recruiting patients for Epidermal disease

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Epidermal disease

Which specialists treat Epidermal disease?

25 specialists and care centers treating Epidermal disease are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.